MedTrace Logo

Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome

NCT02452983 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-06-02

No results posted yet for this study

Summary

This study will investigate the effects of sertraline in people with low-risk myelodysplastic syndrome (MDS). It is hoped that sertraline will decrease disease progression and reduce the need for blood transfusions.

Conditions

Interventions

DRUG

Sertraline

PROCEDURE

Bone Marrow Aspirate/Biopsy

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • Gustavo Rivero

    lead OTHER

Principal Investigators

  • Gustavo A Rivero, MD · Baylor College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02452983 on ClinicalTrials.gov